The adaptor protein MyD88 is involved in interleukin 1 receptor and Toll-like receptor signaling. Unexpectedly, new evidence shows that MyD88 also participates in interferon-γ-induced cellular ...
Polymerase chain reaction with allele-specific oligonucleotides (ASO-PCR) is a technique that can discriminate low levels of the mutant sequence against a background high in wild-type DNA. 14 In ...
In a recent study published in the Journal of Experimental Medicine, researchers identified that individuals with a deficiency of myeloid differentiation primary response 88 (MyD88) and interleukin-1 ...
We performed a prospective study of ibrutinib in 63 symptomatic patients with Waldenström’s macroglobulinemia who had received at least one previous treatment, and we investigated the effect of MYD88 ...
Even if you don't have allergies yourself, I guarantee you can list at least three people you know who have allergies. Asthma, a respiratory disorder commonly associated with allergies, afflicts over ...
Correlation between 24-hour proteinuria and spot urine albumin to creatinine ratio in systemic light chain amyloidosis. GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, ...
A phase I study of the toll-like receptor 5 (TLR5) agonist, entolimod in patients (pts) with advanced cancers. A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human ...
Researchers from Wenzhou Medical University and affiliated organizations presented the discovery and preclinical characterization of novel myeloid differentiation primary response 88 (MyD88) inhibitor ...
Single-agent ibrutinib has shown substantial activity in patients with relapsed Waldenström’s macroglobulinemia, a rare form of B-cell lymphoma. We evaluated the effect of adding ibrutinib to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results